Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Cereblon ( CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium

Blood (2014) 124 (21): 3628.

https://doi.org/10.1182/blood.V124.21.3628.3628

Published: 2014

Journal Articles

Increasing Efficacy of Autologous Haematopoetic Cell Transplantation in Acute Myeloblastic Leukaemia; a Single Centre Experience in 141 Patients.

Jerzy Holowiecki Prof, Tomasz Czerw, MD, Jerzy Wojnar, MD, PhD, Malgorzata Krawczyk-Kulis, MD, PhD, Sebastian Grosicki, MD, Beata Stella-Holowiecka, MD, PhD, Slawomira Kyrcz-Krzemien Prof, Maria Sadus-Wojciechowska, MD, Sebastian Giebel, MD, Lucja Kachel, MD, Krzysztof Wozniczka, MD, Aleksandra Holowiecka-Goral, MD

Blood (2007) 110 (11): 2875.

https://doi.org/10.1182/blood.V110.11.2875.2875

Published: 2007

Journal Articles

The Impact of NOD2/CARD15 and KIR Polymorphisms on the Incidence of Infectious Complications in allo-HSCT Recipients.

Aleksandra Holowiecka-Goral, MD, Sebastian Giebel, MD, Izabela Nowak, PhD, Tomasz Czerw, MD, Jerzy Wojnar, MD, Malgorzata Krawczyk-Kulis, MD, Elzbieta Pietruszka, PhD, Miroslaw Markiewicz, MD, Piotr Kusnierczyk, MD, Iwona Wylezol, MD, Jerzy Holowiecki Prof

Blood (2007) 110 (11): 2968.

https://doi.org/10.1182/blood.V110.11.2968.2968

Published: 2007

Journal Articles

Treosulfan-Based Reduced Toxicity Regimen Prior to Allogeneic Hematopoietic Cell Transplantation in Non-Malignant Disorders.

Jerzy Wojnar, MD, Sebastian Giebel, MD, Miroslaw Markiewicz, MD, Malgorzata Krawczyk-Kulis, MD, Iwona Wylezol, MD, Beata Stella-Holowiecka, MD, Tomasz Kruzel, MD, Jerzy Holowiecki

Blood (2006) 108 (11): 5245.

https://doi.org/10.1182/blood.V108.11.5245.5245

Published: 2006

Journal Articles

Treosulfan, Fludarabine, and Antithymocyte Globulin - A Low Toxicity Conditioning Regimen for Unrelated Donor - Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia.

Jerzy Holowiecki, Sebastian Giebel, MD, Jerzy Wojnar, MD, Miroslaw Markiewicz, MD, Aleksandra Holowiecka-Goral, MD, Iwona Wylezol, MD, Malgorzata Krawczyk-Kulis, MD, Krzysztof Wozniczka, MD

Blood (2006) 108 (11): 2948.

https://doi.org/10.1182/blood.V108.11.2948.2948

Published: 2006

Journal Articles

Autologous Transplantation of Non-Cryopreserved Bone Marrow for the Treatment of High-Risk Adult Acute Lymphoblastic Leukemia in First Complete Remission.

Jerzy Holowiecki, Sebastian Giebel, MD, Malgorzata Krawczyk-Kulis, MD, Maria Sadus-Wojciechowska, MD, Lucja Kachel, MD, Jerzy Wojnar, MD, Beata Stella-Holowiecka, MD, Sebastian Grosicki, MD

Blood (2005) 106 (11): 5492.

https://doi.org/10.1182/blood.V106.11.5492.5492

Published: 2005

Journal Articles

Impact of Activating Killer Immunoglobulin-Receptor Genotype of the Donor on Outcome of Unrelated Donor - Hematopoietic Stem Cell Transplantation.

Sebastian Giebel, MD, Izabela Nowak, PhD, Tomasz Kruzel, MD, Jerzy Wojnar, MD, Miroslaw Markiewicz, MD, Joanna Dziaczkowska, MD, Iwona Wylezol, MD, Malgorzata Krawczyk-Kulis, MD, Renata Bloch, PhD, Tomasz Czerw, MD, Agnieszka Karolczyk, PhD, Piotr Kusnierczyk, PhD, Jerzy Holowiecki

Blood (2005) 106 (11): 5206.

https://doi.org/10.1182/blood.V106.11.5206.5206

Published: 2005

Journal Articles

Treosulfan + Fludarabine +/− Thymoglobulin - An Effective Low Toxicity Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia.

Jerzy Holowiecki, Sebastian Giebel, MD, Jerzy Wojnar, MD, Malgorzata Krawczyk-Kulis, MD, Iwona Wylezol, MD, Miroslaw Markiewicz, MD, Tomasz Kruzel, MD, Aleksandra Holowiecka-Goral, MD, Malgorzata Kopera, MD

Blood (2005) 106 (11): 5309.

https://doi.org/10.1182/blood.V106.11.5309.5309

Published: 2005

Journal Articles

Multiple Transplant-Related Risk Factors for Hemolysis Including Major Kidd-Group Incompatibility Did Not Influence the Favourable Course of Unrelated Donor Bone Marrow Transplantation for Paroxysmal Nocturnal Hemoglobinuria.

Miroslaw Markiewicz, MD, Iwona Wylezol, MD, Sebastian Giebel, MD, Malgorzata Krawczyk-Kulis, MD, Jerzy Wojnar, MD, Ewa Mendek-Czajkowska, MD, Jerzy Holowiecki

Blood (2005) 106 (11): 5444.

https://doi.org/10.1182/blood.V106.11.5444.5444

Published: 2005

Journal Articles

Impact of HLA Class I Typing-Resolution and Mismatches on Survival and Graft-Versus-Host Disease in Patients after Hematopoietic Stem Cell Transplantations from Unrelated Donors.

Miroslaw Markiewicz, MD, Jerzy Wojnar, MD, Malgorzata Krawczyk-Kulis, MD, Iwona Wylezol, MD, Sebastian Giebel, MD, Jerzy Holowiecki

Blood (2005) 106 (11): 2060.

https://doi.org/10.1182/blood.V106.11.2060.2060

Published: 2005

Journal Articles

Daunorubicin, Cytarabine and Fludarabine (DAF) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Phase II Study by the Polish Adult Leukemia Group (PALG).

Jerzy Holowiecki, Sebastian Grosicki, MD, Slawomira Krzemien, MD, Aleksander Skotnicki, Krzysztof Warzecha, Barbara Zdziarska, MD, Beata Stella-Holowiecka, MD, Malgorzata Krawczyk-Kulis, MD, Malgorzata Kopera, MD, Maria Wojciechowska, MD

Blood (2004) 104 (11): 4507.

https://doi.org/10.1182/blood.V104.11.4507.4507

Published: 2004

Journal Articles

Time-Sequenced G-CSF (Lenograstim) for the Treatment of Adult Acute Lymphoblastic Leukemia - Seven Year Follow-Up of the Polish Adult Leukemia Group 4–96 Study.

Sebastian Giebel, MD, Jerzy Holowiecki, Malgorzata Krawczyk-Kulis, MD, Slawomira Kyrcz-Krzemien, MD, Andrzej Hellmann, Anna Dmoszynska, Monika Paluszewska, MD, Tadeusz Robak, Lech Konopka, Ilona Seferynska, MD, Aleksander Skotnicki, Wojciech Baran, MD, Maria Adamczyk-Cioch, MD, Agata Wrzesien-Kus, MD, Krystyna Jagoda, PhD

Blood (2004) 104 (11): 2733.

https://doi.org/10.1182/blood.V104.11.2733.2733

Published: 2004

Journal Articles

Immunophenotyping to Detect Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia - Feasibility and Prognostic Significance.

Jerzy Holowiecki, Sebastian Giebel, MD, Krystyna Jagoda, PhD, Malgorzata Krawczyk-Kulis, MD, Beata Stella-Holowiecka, MD, Slawomira Kyrcz-Krzemien, MD, Monika Paluszewska, MD, Malgorzata Kopera, MD, Wlodzimierz Medrek, MD, Grazyna Bober, MD, Jacek Najda, MD

Blood (2004) 104 (11): 4489.

https://doi.org/10.1182/blood.V104.11.4489.4489

Published: 2004

Journal Articles

Addition of Purine Analogues to Induction/Consolidation Regimen Does Not Impair Peripheral Blood Stem Cell Mobilization and Bone Marrow Harvest for Autotransplantation in Acute Myeloid Leukemia.

Jerzy Holowiecki, Sebastian Grosicki, MD, Andrzej Hellmann, Aleksander Skotnicki, Wieslaw W. Jedrzejczak, Anna Dmoszynska, Bozena Marianska, Tadeusz Robak, Sebastian Giebel, MD, Jerzy Wojnar, MD, Malgorzata Krawczyk-Kulis, MD, Maria Wojciechowska, MD

Blood (2004) 104 (11): 5198.

https://doi.org/10.1182/blood.V104.11.5198.5198

Published: 2004

Journal Articles

The Impact of Immunosuppressive Therapy on an Early Quantitative Reconstitution of NK Cells after Allogeneic Hematopoietic Stem Cell Transplantation.

Sebastian Giebel, MD, Joanna Dziaczkowska, PhD, Iwona Wylezol, MD, Jerzy Wojnar, MD, Malgorzata Krawczyk-Kulis, MD, Krystyna Jagoda, PhD, Aleksandra Holowiecka-Goral, MD, Jerzy Holowiecki

Blood (2004) 104 (11): 4946.

https://doi.org/10.1182/blood.V104.11.4946.4946

Published: 2004

Journal Articles

Treosulfan-Based Myeloablative Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Is Associated with Reduced Toxicity without Increased Risk of Relapse.

Sebastian Giebel, MD, Jerzy Wojnar, MD, Malgorzata Krawczyk-Kulis, MD, Iwona Wylezol, MD, Miroslaw Markiewicz, MD, Tomasz Kruzel, MD, Jerzy Holowiecki, MD

Blood (2004) 104 (11): 1152.

https://doi.org/10.1182/blood.V104.11.1152.1152

Published: 2004

Journal Articles

Treosulfan/Fludarabine - a Low Toxicity but Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia.

Jerzy Holowiecki, Sebastian Giebel, MD, Jerzy Wojnar, MD, Malgorzata Krawczyk-Kulis, MD, Iwona Wylezol, MD, Tomasz Kruzel, MD, Miroslaw Markiewicz, MD

Blood (2004) 104 (11): 1022.

https://doi.org/10.1182/blood.V104.11.1022.1022

Published: 2004

Journal Articles

Single Immunophenotypical Evaluation of Minimal Residual Disease before Autotransplantation of Non-Cryopreserved Bone Marrow Is Insufficient for Prediction of Outcome in High Risk Adult Acute Lymphoblastic Leukemia.

Beata M. Stella-Holowiecka, MD, Krystyna Jagoda, MD, Aleksandra M. Holowiecka-Goral, MD, Tomasz Czerw, MD, Sebastian Giebel, MD, Malgorzata Krawczyk-Kulis, MD, Jerzy Holowiecki, MD, PhD

Blood (2004) 104 (11): 4439.

https://doi.org/10.1182/blood.V104.11.4439.4439

Published: 2004

Journal Articles

CD52 and CD20 as Potential Targets for Anti-Leukemic Immunotherapy in Adult Acute Lymphoblastic Leukemia.

Krystyna Jagoda, PhD, Sebastian Giebel, MD, Beata Stella-Holowiecka, MD, Malgorzata Krawczyk-Kulis, MD, Jerzy Holowiecki

Blood (2004) 104 (11): 4403.

https://doi.org/10.1182/blood.V104.11.4403.4403

Published: 2004

Journal Articles

Lower Relapse Incidence after Non-Cryopreserved Autologous Bone Marrow Transplantation Compared to Peripheral Blood Stem Cell Transplantation for High-Risk Hodgkin’s Lymphoma.

Jerzy Holowiecki, Sebastian Giebel, MD, Malgorzata Krawczyk-Kulis, MD, Jerzy Wojnar, MD, Lucja Kachel, MD, Maria Sadus-Wojciechowska, MD, Beata Stella-Holowiecka, MD, Sebastian Grosicki, MD, Tomasz Czerw, MD

Blood (2004) 104 (11): 912.

https://doi.org/10.1182/blood.V104.11.912.912

Published: 2004

NARROW

Cereblon ( CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium

Increasing Efficacy of Autologous Haematopoetic Cell Transplantation in Acute Myeloblastic Leukaemia; a Single Centre Experience in 141 Patients.

The Impact of NOD2/CARD15 and KIR Polymorphisms on the Incidence of Infectious Complications in allo-HSCT Recipients.

Treosulfan-Based Reduced Toxicity Regimen Prior to Allogeneic Hematopoietic Cell Transplantation in Non-Malignant Disorders.

Treosulfan, Fludarabine, and Antithymocyte Globulin - A Low Toxicity Conditioning Regimen for Unrelated Donor - Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia.

Autologous Transplantation of Non-Cryopreserved Bone Marrow for the Treatment of High-Risk Adult Acute Lymphoblastic Leukemia in First Complete Remission.

Impact of Activating Killer Immunoglobulin-Receptor Genotype of the Donor on Outcome of Unrelated Donor - Hematopoietic Stem Cell Transplantation.

Treosulfan + Fludarabine +/− Thymoglobulin - An Effective Low Toxicity Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia.

Multiple Transplant-Related Risk Factors for Hemolysis Including Major Kidd-Group Incompatibility Did Not Influence the Favourable Course of Unrelated Donor Bone Marrow Transplantation for Paroxysmal Nocturnal Hemoglobinuria.

Impact of HLA Class I Typing-Resolution and Mismatches on Survival and Graft-Versus-Host Disease in Patients after Hematopoietic Stem Cell Transplantations from Unrelated Donors.

Daunorubicin, Cytarabine and Fludarabine (DAF) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Phase II Study by the Polish Adult Leukemia Group (PALG).

Time-Sequenced G-CSF (Lenograstim) for the Treatment of Adult Acute Lymphoblastic Leukemia - Seven Year Follow-Up of the Polish Adult Leukemia Group 4–96 Study.

Immunophenotyping to Detect Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia - Feasibility and Prognostic Significance.

Addition of Purine Analogues to Induction/Consolidation Regimen Does Not Impair Peripheral Blood Stem Cell Mobilization and Bone Marrow Harvest for Autotransplantation in Acute Myeloid Leukemia.

The Impact of Immunosuppressive Therapy on an Early Quantitative Reconstitution of NK Cells after Allogeneic Hematopoietic Stem Cell Transplantation.

Treosulfan-Based Myeloablative Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Is Associated with Reduced Toxicity without Increased Risk of Relapse.

Treosulfan/Fludarabine - a Low Toxicity but Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia.

Single Immunophenotypical Evaluation of Minimal Residual Disease before Autotransplantation of Non-Cryopreserved Bone Marrow Is Insufficient for Prediction of Outcome in High Risk Adult Acute Lymphoblastic Leukemia.

CD52 and CD20 as Potential Targets for Anti-Leukemic Immunotherapy in Adult Acute Lymphoblastic Leukemia.

Lower Relapse Incidence after Non-Cryopreserved Autologous Bone Marrow Transplantation Compared to Peripheral Blood Stem Cell Transplantation for High-Risk Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only